Clinical trial · Observational
Mechanisms, Predictors, and Social Determinants of Cardiotoxicity in Breast Cancer
Cardiotoxicity of Cancer Therapy 2: Mechanisms, Predictors, and Social Determinants of Health in Breast Cancer Patients Treated With Doxorubicin and/or Trastuzumab
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
This is an observational study for patients with breast cancer that will be treated with doxorubicin (Adriamycin) and/or trastuzumab (Herceptin). The study will help the investigators learn more about how these medications affect the heart and how those effects relate to patients' medical history and social determinants of health (such as race, gender identity, education, occupation, access to health services and economic resources). Patients on this study will have echocardiograms, blood draws, and answer questions about their symptoms and activity level. Patients will be followed on this study for up to 15 years.
Conditions
Conditions (4)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Breast Cancer | Malignant Breast Neoplasm | CURATED_EXACT | 0.92 |
| Cardiotoxicity | — | UNRESOLVED | — |
| Cardiovascular Diseases | — | UNRESOLVED | — |
| Drug-Related Side Effects and Adverse Reactions | — | UNRESOLVED | — |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Social Determinants of Health | Other | — | UNRESOLVED |
Design
Arms and outcomes
Arms (3)
- label
- Doxorubicin
- description
- Patients treated with doxorubicin (Adriamycin) for breast cancer
- interventionNames
- Other: Social Determinants of Health
- label
- Trastuzumab
- description
- Patients treated with trastuzumab (Herceptin) for breast cancer
- interventionNames
- Other: Social Determinants of Health
- label
- Doxorubicin and Trastuzumab
- description
- Patients treated with both doxorubicin (Adriamycin) and trastuzumab (Herceptin) for breast cancer
- interventionNames
- Other: Social Determinants of Health
Primary outcomes (1)
Eligibility
Eligibility (as posted)
- Sex
- Female
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Women older than 18 years of age * Breast cancer with treatment plan that includes doxorubicin and/or trastuzumab * Ability to provide written informed consent Exclusion Criteria: * Pregnancy at enrollment * Inability or unwillingness to provide consent
References
Publications (1)
- DERIVEDBarrett M, Wilcox NS, Huang A, Levy R, Demissei B, Narayan V, Ky B. Bearing allostatic load: insights into a more equitable future within cardio-oncology. Trends Mol Med. 2022 Dec;28(12):1040-1049. doi: 10.1016/j.molmed.2022.09.006. Epub 2022 Oct 4. PMID 36207229